Diabetic Kidney Disease Market Forecast, Trends, Opportunities And Growth 2025-2034

Use Code ONLINE20 to Save 20% On Global Market Reports – Gain Access to Trusted Market Data, Growth Indicators, and Industry Analytics

What Is the Forecasted Market Size of the Diabetic Kidney Disease Market by 2029?
The diabetic kidney disease market size has grown steadily in recent years. It will grow from $2.67 billion in 2024 to $2.8 billion in 2025 at a compound annual growth rate (CAGR) of 4.8%. The growth in the historic period can be attributed to early understanding of diabetes complications, advancements in diagnostic techniques, development of ace inhibitors and arbs, clinical trials and treatment protocols, guidelines and disease management protocols.

The diabetic kidney disease market size is expected to see strong growth in the next few years. It will grow to " $3.53 billion in 2029 at a compound annual growth rate (CAGR) of 6.0%. The growth in the forecast period can be attributed to personalized medicine and biomarker development, rising global diabetes incidence, focus on disease modification therapies, telehealth and remote care, healthcare policy and reimbursement changes. Major trends in the forecast period include advancements in renal replacement therapies, precision medicine approach, focus on early detection and diagnosis, therapeutic advancements, rise in comorbidities management.

Get your free report sample today:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9932&type=smp

What Are the Significant Market Forces Driving the Diabetic Kidney Disease Market Performance?
The rising prevalence of chronic kidney disease is expected to propel the growth of the diabetic kidney disease market. Chronic kidney disease (CKD) refers to a long-term condition that results in the loss of kidney function over time causing a number of complications such as high blood pressure, anemia, and bone diseases. The treatment of chronic kidney diseases requires diagnostic and treatment options, ultimately fueling the growth of the diabetic kidney disease market. For instance, in June 2023, according to the Kidney Research UK, a UK-a prominent charity, chronic kidney disease (CKD) affects around 7.2 million people in the United Kingdom, accounting for more than 10% of the population. Among these, 3.25 million are in the most severe stages of the disease, while around 3.9 million are in the early stages, which are frequently untreated and asymptomatic. According to projections, the overall number of people with chronic renal disease in the United Kingdom could reach 7.61 million by 2033. Therefore, the rising prevalence of chronic kidney disease is driving the growth of the diabetic kidney disease market going forward.

What Are the Primary Market Segments in the Diabetic Kidney Disease Market?
The diabetic kidney diseasemarket covered in this report is segmented –

1) By Type: Type 1 Diabetes; Type 2 Diabetes
2) By Treatment: Angiotensin Receptor Blockers (Arbs); Angiotensin-Converting Enzyme (Ace) Inhibitors; Antioxidant Inflammation Modulator; Calcium Channel Blockers; Other Treatments
3) By End User: Hospitals; Homecare; Specialty Centers; Other End Users

Subsegments:
1) By Type 1 Diabetes: Autoimmune-Related Diabetic Kidney Disease; Early-Onset Diabetic Kidney Disease
2) By Type 2 Diabetes: Obesity-Related Diabetic Kidney Disease; Late-Onset Diabetic Kidney Disease

Which Future-Ready Trends Are Expected to Influence the Diabetic Kidney Disease Market?
Technological advancements are a key trend gaining popularity in the diabetic kidney disease market. Companies operating in the diabetic kidney disease market are adopting new technologies to sustain their position in the market. For instance, in August 2022, Bloom Diagnostics, a US-based diagnostics and healthcare devices organization, launched the Bloom Kidney Test, a new tool that can be integrated with the Bloom Smart System. The Bloom Kidney Test is a diagnostic tool that assesses kidney health by measuring cystatin C levels, which is a reliable indicator of kidney function. It classifies kidney function into three categories: normal, mildly decreased, and decreased. The Bloom Smart System leverages cloud-based algorithms and AI (artificial intelligence) technology to integrate test results with other relevant health information, such as medical history, lifestyle, and symptoms of the patient.

Who Are the Established and Emerging Companies Competing in the Diabetic Kidney Disease Market?
Major companies operating in the diabetic kidney disease market include AstraZeneca plc, Pfizer Inc., Novartis AG, Bayer AG, Sanofi SA, Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Company, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., Fresenius SE & Co. KGaA, F. Hoffmann-La Roche AG, Abbott Laboratories, Reata Pharmaceuticals Inc., Merck & Co., Mitsubishi Tanabe Pharma Corporation, Johnson & Johnson pvt. Ltd., Eli Lilly and Company, GlaxoSmithKline plc, AbbVie Inc., Boehringer Ingelheim International GmbH, Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Company Limited

Get the detailed diabetic kidney disease market report today
https://www.thebusinessresearchcompany.com/report/diabetic-kidney-disease-global-market-report

Which Region Is Expected to Dominate the Diabetic Kidney Disease Market During the Forecast Period?
North America was the largest region in the diabetic kidney disease market in 2024. The regions covered in the diabetic kidney disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Contact Us:
The Business Research Company: https://thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info

Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company